###begin article-title 0
###xml 30 37 30 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma
###end article-title 0
###begin p 1
Conceived and designed the experiments: NC PH MT LB JPS SW. Performed the experiments: NC PH MT LB JPS SW. Analyzed the data: PLM NC SW. Contributed reagents/materials/analysis tools: NC. Wrote the paper: PLM NC PH SW.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
Although the increase in risk of developing breast, ovarian, and prostate cancer in BRCA1 and BRCA2 mutation carriers has been studied extensively, its impact on mortality is not well quantified. Further, possible effect of BRCA mutations on non-cancer mortality risk has not been examined.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 95 99 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1322 1329 1322 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 59 71 <span type="species:ncbi:9606">participants</span>
###xml 1139 1144 <span type="species:ncbi:9606">women</span>
###xml 1184 1187 <span type="species:ncbi:9606">men</span>
###xml 1244 1247 <span type="species:ncbi:9606">men</span>
###xml 1252 1257 <span type="species:ncbi:9606">women</span>
Using mortality data from the relatives of 5,287 genotyped participants, of whom 120 carried a BRCA Ashkenazi Jewish founder mutation, in a community-based study of the Ashkenazi Jewish population in the Washington D.C area, we examined the association between the three Ashkenazi BRCA founder mutations and risk of overall and non-cancer mortality. To examine risks beyond the established effects of these mutations, we analyzed the data excluding both deaths and follow-up times after reported diagnosis of melanoma and cancer of the breast, ovary, prostate, and pancreas. Using an extension of the kin-cohort method that accounts for informative censoring, we estimated that, in the absence of breast, ovarian, and pancreatic cancers, and melanoma, female carriers had a life expectancy that was 6.8 years lower (95% CI: 1.2-10.5) than non-carriers. In male mutation carriers, the reduction in life expectancy, in the absence of prostate and pancreatic cancers and melanoma, was 3.7 (95% CI: -0.4, 6.8) years. When deaths and follow-up times after any cancer diagnosis were excluded, the difference in life expectancy was 5.7 years for women (95% CI: -0.1, 10.4) and 3.7 years for men (95% CI: -0.4, 6.9). An overall test of association for men and women together showed a statistically significant association between BRCA1/2 mutations and increased non-cancer mortality (p = 0.024).
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
These findings suggest that there may be unknown effects of BRCA1/2 mutations on non-neoplastic diseases that cause death at older ages.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 43 50 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 146 149 146 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Ford1">[1]</xref>
###xml 150 153 150 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Chen1">[9]</xref>
###xml 212 219 212 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 307 310 307 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-The1">[8]</xref>
###xml 312 316 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Tai1">[10]</xref>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Risch1">[12]</xref>
###xml 382 389 382 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 512 516 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Risch1">[12]</xref>
Germline mutations in the BRCA1 and BRCA2 (BRCA1/2) tumor suppressor genes are highly penetrant for increased risks of breast and ovarian cancers [1]-[9]. Other cancers that have been shown to be associated with BRCA1/2 mutations include male breast cancer, prostate cancer, pancreatic cancer, and melanoma [8], [10]-[12]. A recent population-based study from Canada suggested that BRCA1/2 mutations were associated with a significantly increased risk of cancers overall and at sites other than breast and ovary [12].
###end p 9
###begin p 10
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Boulton1">[13]</xref>
###xml 240 247 240 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 337 344 337 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Grann1">[14]</xref>
###xml 460 467 460 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 548 553 548 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 637 642 637 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 672 677 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 754 759 754 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 764 769 764 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 826 830 826 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Byrd1">[15]</xref>
###xml 895 902 895 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
Although the exact role of these genes on carcinogenesis is not fully understood, existing data suggest that they play a key role in DNA damage repair and the maintenance of genomic stability [13]. Very little is known about the effects of BRCA1/2 mutations on phenotypes other than cancer. Moreover, although overall life expectancy in BRCA1/2 mutation carriers has been estimated, using simulation models, to be decreased [14], the actual impact of having a BRCA1/2 mutation on life expectancy is not known. A recent actuarial analysis in female BRCA1 and BRCA2 mutation carriers showed that mortality risk by age 70 was greater among BRCA1 mutation carriers than among BRCA2 mutation carriers; and that the major contributing causes of death for both BRCA1 and BRCA2 mutation carriers were breast cancer and ovarian cancer [15]. There has been no report to date on non-cancer mortality among BRCA1/2 mutation carriers.
###end p 10
###begin p 11
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 240 247 240 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 392 399 392 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 487 491 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Chatterjee1">[16]</xref>
To examine the effect of BRCA1/2 mutations on mortality apart from their known effects on cancer risk, we studied the association between mutations and mortality in the absence of cancer in a cohort of first-degree relatives (FDR) of known BRCA1/2 mutation carriers and non-carriers. We were able to use a kin-cohort analysis that accounts for informative censoring to estimate the effect of BRCA1/2 mutations on mortality with the effect of mortality directly related to cancer removed [16].
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
Ethics Statement
###end title 13
###begin p 14
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 365 370 <span type="species:ncbi:9606">Human</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
This study was conducted according to the principles expressed in the Declaration of Helsinki. Use of human subject data in this study was approved by the Special Study Institutional Review Board and Clinical Center Institutional Review Board of the National Cancer Institute, in accordance with an assurance filed with and approved by the Department of Health and Human Services. All patients provided written informed consent for the collection of samples and subsequent analysis.
###end p 14
###begin p 15
###xml 102 105 102 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Struewing1">[6]</xref>
###xml 139 146 139 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 338 341 338 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Struewing1">[6]</xref>
###xml 768 773 768 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 790 795 790 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 49 61 <span type="species:ncbi:9606">participants</span>
###xml 203 206 <span type="species:ncbi:9606">men</span>
###xml 211 216 <span type="species:ncbi:9606">women</span>
###xml 370 373 <span type="species:ncbi:9606">men</span>
###xml 378 383 <span type="species:ncbi:9606">women</span>
###xml 586 598 <span type="species:ncbi:9606">participants</span>
###xml 921 933 <span type="species:ncbi:9606">participants</span>
###xml 1122 1134 <span type="species:ncbi:9606">participants</span>
###xml 1391 1399 <span type="species:ncbi:9606">children</span>
We used data available from the cohort of FDR of participants in the Washington Ashkenazi Study (WAS) [6] to study the association between BRCA1/2 mutations and mortality risk at different ages for both men and women. Details of subject recruitment methods, data collection and laboratory testing for the WAS have been reported elsewhere [6]. In brief, Ashkenazi Jewish men and women living in the Washington D.C area were recruited through public media such as posters, newspaper, and radio announcements. A total of 5,318 volunteers were enrolled over a nine-week period in 1996. All participants provided blood samples after giving written informed consent. Genotyping for the three specific Ashkenazi founder mutations in this population, 5382insC and 185delAG in BRCA1 and 6174delT in BRCA2, was performed with PCR-based assays for all individuals enrolled in the WAS. Through a self-administered questionnaire, the participants also provided detailed information regarding their family history of cancer, including age at diagnosis, vital status information, year of birth and year of death, for all FDR. Thirty one participants who did not contribute any relative with known vital status were excluded from this report. Cause of death was not ascertained and could not be retrieved because the data were anonymized. First-degree relatives were categorized into parents, siblings, and children. For families in which two or more family members participated in the study, only one member was selected in the determination of carrier status for FDR; thus no relative was included more than once. If volunteers from the same family included a mutation carrier and a non-carrier, the mutation carrier was used as the proband.
###end p 15
###begin p 16
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Wacholder1">[17]</xref>
###xml 1082 1085 1082 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Struewing1">[6]</xref>
###xml 1087 1091 1087 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Wacholder1">[17]</xref>
###xml 1121 1125 1121 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Lee1">[18]</xref>
###xml 1280 1287 1280 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 619 631 <span type="species:ncbi:9606">participants</span>
###xml 1180 1192 <span type="species:ncbi:9606">participants</span>
We previously described the "kin-cohort" analytic approach, demonstrating how the penetrance of a disease related to a genetic mutation can be estimated from the disease history data of the relatives of genotyped subjects [17]. This method relies on the basic principle that, although the genotype of the relatives are not known, one can use Mendelian laws to estimate the expected proportions of carriers and non-carriers among the relatives of the genotyped individuals; alternatively, one can think of the cohort of relatives as having "missing" genotypes, whose distribution can be inferred via Mendelian laws from participants who were genotyped. Generally, the proportion of carriers of a rare mutation will be much higher in close relatives of a mutation carrier than in relatives of a mutation non-carrier. We can test the association between mutation and disease, as well as estimate genotype-specific absolute risk (penetrance) for the disease using the inferred genotype distribution for all relatives. Following the same principles as in our studies of cancer incidence [6], [17] and survival after diagnosis [18], we used mortality data from the relatives of the WAS participants to obtain age-specific cumulative risks and hazards (interval risk) of mortality among BRCA1/2 mutation carriers and non-carriers.
###end p 16
###begin title 17
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
Mortality in the absence of BRCA-related cancers
###end title 17
###begin p 18
###xml 145 152 145 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 236 240 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Wacholder1">[17]</xref>
###xml 242 246 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Chatterjee2">[19]</xref>
###xml 247 251 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Moore1">[21]</xref>
###xml 368 375 368 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Chatterjee1">[16]</xref>
We treated a diagnosis of breast, ovarian, prostate, pancreatic cancer, or melanoma as a censoring event to eliminate the established effects of BRCA1/2 mutations on mortality risk. Unlike previous applications of kin-cohort estimation [17], [19]-[21], we could not assume that the censoring events were independent of the mutations under study because diagnosis of a BRCA1/2 mutation-related cancer made the unknown genotype more likely to include a mutation. The analytic approach of Chatterjee and Wacholder [16] accounts for possible bias due to this dependent censoring. We estimated hazards of mortality for carriers and non-carriers in 10-year intervals and plotted the non-parametric estimate of the age-specific cumulative risk functions. We estimated life expectancy by numeric integration of the survival function, i.e. the complement of the cumulative-risk function, over the observed range of ages at mortality in the data. We obtained confidence intervals and standard error for parameter estimated by bootstrap sampling (500 replicates) of the WAS families in a way that automatically accounts for the correlation of the relatives within a family. For a global test of the difference in mortality risk between carriers and non-carriers, we compared their average life-expectancies based on estimates of the age-specific risk of mortality. Wald statistics were computed by parameter estimates divided by their bootstrap standard errors, and the associated p-values were reported.
###end p 18
###begin title 19
Mortality in the absence of all cancer
###end title 19
###begin p 20
We also estimated mortality risk in the absence of any cancer diagnosis using the same method with follow-up censored at the time of cancer diagnosis at any site.
###end p 20
###begin p 21
To examine possible impact of birth cohort effects in our analysis, we first performed tests for interactions in the Cox proportional hazard regression model to detect potential differences in the mortality risk between carriers and non-carriers by birth cohort. As no significant differences were found, we adjusted for the effect of birth cohort assuming the effect on mortality is the same for both carriers and non-carriers.
###end p 21
###begin title 22
Results
###end title 22
###begin p 23
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 299 306 299 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004812-t001">Table 1</xref>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 140 148 <span type="species:ncbi:9606">children</span>
###xml 158 170 <span type="species:ncbi:9606">participants</span>
Participants who tested positive for one of the BRCA Ashkenazi founder mutations reported having a higher proportion of female siblings and children than did participants who tested negative. On average, mutation carriers and their relatives were born earlier than non-carriers and their relatives (Table 1). Twenty-seven percent of relatives of carriers were dead at the time of the study, compared with 25% of relatives of non-carriers. Ten percent of siblings of carriers were dead at the time of the study, compared with 16% of siblings of non-carriers. On the average, siblings of carriers were born four years later than siblings of non-carriers. Deceased parents and siblings of carriers had younger ages at death than parents and siblings of non-carriers.
###end p 23
###begin title 24
###xml 27 39 <span type="species:ncbi:9606">participants</span>
Descriptive statistics for participants and first-degree relatives from the Washington Ashkenazi Study.
###end title 24
###begin p 25
Among deceased relatives.
###end p 25
###begin p 26
Chi-squared test for percentages or two-sample t-test for continuous variables.
###end p 26
###begin p 27
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004812-g001">Figure 1</xref>
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Chatterjee1">[16]</xref>
Figure 1 shows the all-cause mortality for the cohort of female FDR of mutation carriers and non-carriers (panel 1) and the mortality risk in female carriers and non-carriers as estimated by the Chatterjee-Wacholder kin-cohort estimation method [16] (panel 2). The cumulative incidence of deaths among female FDR of carriers was higher than that for female FDR of non-carriers.
###end p 27
###begin title 28
Cumulative incidence of all-cause mortality.
###end title 28
###begin p 29
###xml 272 279 272 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 101 113 <span type="species:ncbi:9606">participants</span>
Panel 1 shows the cumulative incidence of all-cause mortality among female first-degree relatives of participants in the Washington Ashkenazi Study. Panel 2 shows the corresponding kin-cohort estimate of cumulative mortality risk among female carriers and non-carriers of BRCA1/2 Ashkenazi Jewish founder mutations.
###end p 29
###begin title 30
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
Mortality in the absence of BRCA-related cancers
###end title 30
###begin p 31
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004812-t002">Table 2</xref>
###xml 644 653 644 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004812-g002">Figure 2A</xref>
Table 2 shows the estimated mortality after excluding deaths and follow-up time in survivors of cancers of the breast, ovary, pancreas, or prostate, or melanoma by the modified kin-cohort method that accounts for dependent censoring. Mortality risk in female mutation carriers is elevated compared with female non-carriers in a number of age groups with the increase being more than twice and statistically significant at ages 71-80. The estimated cumulative mortality up to age 80, excluding time after breast, ovarian, pancreatic cancer and melanoma diagnosis, was 36% (95% CI: 34, 39) for non-carriers and 71% (95% CI: 47, 90) for carriers (Figure 2A). We further estimated that, in the absence of these cancers, the average life expectancy was 80.8 (95% CI: 80.4, 81.3) years for non-carriers and 75.0 (95% CI: 70.5, 79.4) years for carriers, or a difference of 6.8 (95% CI: 1.3, 10.5) years.
###end p 31
###begin title 32
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
Cumulative incidence of mortality risk in the absence of established BRCA mutation-associated cancers.
###end title 32
###begin p 33
Estimated cumulative risk of mortality among females in the absence of breast, ovarian, pancreatic cancer, and melanoma is shown in panel A. Panel B shows the estimated cumulative risk of mortality among males in the absence of melanoma, prostate, and pancreatic cancer.
###end p 33
###begin title 34
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="nt103">1</xref>
Estimated hazard of mortality due to carrying a BRCA mutation in the absence of melanoma and cancer of the breast, ovary, pancreas, and prostate1.
###end title 34
###begin p 35
Follow-up time and deaths were censored at first report of melanoma or cancer of the breast, ovary, pancreas, or prostate.
###end p 35
###begin p 36
###xml 158 165 158 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004812-t002">Table 2</xref>
###xml 170 179 170 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004812-g002">Figure 2B</xref>
###xml 4 7 <span type="species:ncbi:9606">men</span>
For men, we saw a similar but more modest effect of the mutations on mortality with censoring at time of melanoma, prostate, and pancreatic cancer diagnosis (Table 2 and Figure 2B). The estimated cumulative mortality risk until age 80 in the absence of these selected cancers was 56% (95% CI: 55, 58) for non-carriers and 77% (95% CI: 58, 90) for carriers. Finally, we estimated that, in the absence of melanoma and pancreatic and prostate cancer, the average life expectancy was 74.7 years (95% CI: 74.3, 75.1) for non-carriers and 71.0 years (95% CI: 68.1, 74.2) for carriers, or a difference of 3.7 (95% CI: 0.4, 6.8) years.
###end p 36
###begin title 37
Mortality in the absence of all cancer
###end title 37
###begin p 38
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 206 213 206 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004812-t003">Table 3</xref>
###xml 218 226 218 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004812-g003">Figure 3</xref>
###xml 276 283 276 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004812-t002">Table 2</xref>
###xml 953 958 953 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 235 240 <span type="species:ncbi:9606">women</span>
Because cancers other than breast, ovary, pancreas, and prostate, and melanoma could be related to BRCA1/2 mutations, we also estimated risks of mortality with censoring at time of diagnosis of any cancer (Table 3 and Figure 3). Among women, the mortality differences seen in Table 2 for the age group 61-70 persisted but at a reduced level. The estimated average life expectancy, in the absence of any cancers, was 5.7 years (95% CI = -0.1, 10.4) greater in female non-carrier than female carriers (83.8 (95% CI = 83.3, 84.3) vs. 78.1 (95% CI = 73.5, 83.9)). Among males, the estimated average life expectancy, in the absence of all cancers, was 78.0 years (95% CI = 77.6, 78.5) for non-carriers and 74.3 years (95% CI = 71.3, 78.1) for carriers - a difference of 3.7 years (95% CI = -0.4, 6.9). Although the difference in life-expectancies between carriers and non-carriers for females and males separately was only marginally significant at the 0.05 alpha-level, a test of association for the difference combining males and females based on Fisher's sum of chi-square statistics was significant with a p-value of 0.024.
###end p 38
###begin title 39
Estimated cumulative risk of mortality in the absence of any cancer.
###end title 39
###begin p 40
The figure shows the estimated cumulative risk of mortality in the absence of any cancer among females (panel A) and males (panel B).
###end p 40
###begin title 41
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="nt104">1</xref>
Estimated hazard of mortality due to carrying a BRCA mutation in the absence of any cancer1.
###end title 41
###begin p 42
Follow-up time and deaths were censored at first report of any cancer.
###end p 42
###begin p 43
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 324 329 324 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 366 371 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 125 130 <span type="species:ncbi:9606">women</span>
###xml 272 275 <span type="species:ncbi:9606">men</span>
We also estimated the overall mortality in the absence of any cancer for BRCA1 and BRCA2 mutation carriers separately. Among women, the difference in life expectancy between carriers and non-carriers was 4.2 years for BRCA1 mutations and 5.5 years for BRCA2 mutation. For men, the corresponding difference was 5.0 years for BRCA1 mutation carriers and 2.7 years for BRCA2 mutation carriers. None of these differences were statistically significant.
###end p 43
###begin p 44
###xml 186 193 186 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 227 232 <span type="species:ncbi:9606">women</span>
###xml 366 374 <span type="species:ncbi:9606">children</span>
###xml 743 748 <span type="species:ncbi:9606">women</span>
###xml 767 770 <span type="species:ncbi:9606">men</span>
Estimates from sensitivity analyses showed consistent effects, though often without statistical significance in subgroups. When adjusted for birth cohort, the excess in mortality due to BRCA1/2 mutations increased slightly for women. The overall pattern of increased estimated mortality risk for carriers was observed in all three generations, parents, siblings and children. We excluded follow-up information referring to time before 1975 to reduce possible bias that may arise due to deaths following unreported cancers that occurred in the distant past; following this exclusion, in the absence of all cancers, the mortality difference between carriers and non-carriers increased; with an estimated gap in life-expectancy of 10.3 years for women and 7.5 years for men.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
In this study, we observed an overall association between BRCA1/2 mutations and reduced life expectancy after excluding deaths following diagnosis of the cancers that have been shown to be related to these mutations. The effects of the mutations were mainly manifested through increased hazard of mortality between ages 61 and 80. Further, the reduction in estimated life expectancy persisted after excluding deaths following any cancer diagnosis.
###end p 46
###begin p 47
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 347 351 347 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Grann1">[14]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Byrd1">[15]</xref>
###xml 372 376 372 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 717 721 717 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Liebens1">[22]</xref>
###xml 722 726 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Robson1">[25]</xref>
###xml 728 732 728 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 896 900 896 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Boyd1">[26]</xref>
###xml 901 905 901 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Cass1">[28]</xref>
###xml 983 987 983 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1188 1192 1188 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
###xml 625 633 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
###xml 869 877 <span type="species:ncbi:9606">patients</span>
To our knowledge, this is the first report to date addressing the affect of BRCA mutations on non-cancer mortality risk. It is commonly thought that overall life expectancy is reduced among BRCA mutation carriers; however, no accurate estimates of this reduction exist, and the contributing cause is thought to be mainly breast and ovarian cancer [14], [15]. Furthermore, BRCA-related breast cancer have been thought to be associated with a worse prognosis than sporadic cases; however, existing data are inconsistent, with several studies suggest that there is no difference in survival between patients with hereditary and patients with sporadic breast cancer, particularly among patients treated with chemotherapy [22]-[25]. BRCA-related ovarian cancer, on the other hand, has been shown to be associated with an improved survival compared with sporadic cases among patients of Jewish descent [26]-[28]. The difference in survival after a breast or ovarian cancer diagnosis among BRCA mutation carriers compared with sporadic cases cannot explain the findings of this report since a mortality difference between among mutation carriers and non-carriers persisted after excluding major BRCA-related cancers as well as all cancers.
###end p 47
###begin p 48
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Boulton1">[13]</xref>
###xml 265 270 265 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Brca1</italic>
###xml 309 312 309 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 318 335 318 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;11/ &#916; 11</sup>
###xml 314 339 314 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Brca<sup>&#916;11/ &#916; 11</sup> p53</italic>
###xml 339 342 331 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 339 342 331 334 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>+/&#8722;</sup></bold>
###xml 344 348 336 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Cao1">[29]</xref>
###xml 382 386 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 498 505 490 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 594 598 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Dizin1">[30]</xref>
###xml 600 604 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Shukla1">[31]</xref>
###xml 212 216 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 459 463 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
BRCA1/2 genes have been shown to play major role in maintaining genomic stability, but the exact mechanism remains unknown [13]. Premature aging with decreased life-span has been observed in animal studies using mice that were homozygous for a hypomorphic mutation Brca1 allele and heterozygous for wild-type p53 (BrcaDelta11/ Delta 11 p53+/-) [29]; however, the mechanism by which BRCA genes exert their affect on mortality is not known. In vivo studies and mice model studies have suggested that BRCA1/2 is involved in translation regulation and the Insulin-Like Growth factor signaling axis [30], [31], but whether these pathways are directly related to premature aging is not clear.
###end p 48
###begin p 49
###xml 325 332 325 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 227 239 <span type="species:ncbi:9606">participants</span>
The major strength of our study is that it is based on a large community sample rather than on high-risk family registries or cancer case series. The retrospectively constructed time of follow-up for the relatives of the study participants gave us a unique opportunity to estimate age-related mortality risks associated with BRCA1/2 mutations.
###end p 49
###begin p 50
###xml 374 381 374 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 80 92 <span type="species:ncbi:9606">participants</span>
###xml 405 417 <span type="species:ncbi:9606">participants</span>
###xml 790 795 <span type="species:ncbi:9606">women</span>
###xml 800 803 <span type="species:ncbi:9606">men</span>
One limitation of our study is the potential bias due to under-reporting by WAS participants of cancer diagnoses in their relatives. The known high risk of certain cancers among carriers could lead to substantial overestimation of mortality risk seemingly from other causes if cancers were under-reported in this group. At the time this study was done, clinical testing for BRCA1/2 was not available, and participants were not aware of their mutation status. Thus, we would not expect differential reporting due to genotype. However, even if the misreporting was non-differential between mutation carriers and non-carriers, the greater number of missed mutation-related cancers in mutation carriers could exaggerate the effects. Nevertheless, the mortality differences we observed for both women and men seem too great to be explained completely by deaths following unreported cancers. Moreover, the findings did not change significantly when the data was limited to relatively recent deaths or stratified by generations. This observation suggests that the apparent mortality difference was unlikely to be entirely due to under-reporting of cancers in relatives.
###end p 50
###begin p 51
###xml 239 246 239 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Chatterjee2">[19]</xref>
###xml 693 697 693 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Lee1">[18]</xref>
###xml 790 794 790 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 865 869 865 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Rennert1">[24]</xref>
###xml 941 945 941 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 969 973 969 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004812-Chetrit1">[27]</xref>
###xml 64 76 <span type="species:ncbi:9606">participants</span>
###xml 930 935 <span type="species:ncbi:9606">women</span>
The major limitation of this report is that the WAS did not ask participants about non-cancer causes of death in relatives. Consequently, we cannot identify specific conditions that might explain the observed association between the three BRCA1/2 Ashkenazi founder mutations and non-cancer mortality. We censored follow-up duration at the time of any cancer diagnosis, and used a statistical method [19] that ensures that the observed association between mutation status and mortality were not due to any reported cancers. Previously, we showed that in this study population, the overall mortality after breast or ovarian cancer diagnosis was similar in relatives of carriers and non-carriers [18]. Moreover, other studies of Ashkenazim have found no difference in overall survival between BRCA mutation carriers and non-carriers after a diagnosis of breast cancer [24], and have suggested a more favorable overall survival among women with BRCA-related ovarian cancer [27].
###end p 51
###begin p 52
###xml 89 96 89 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 293 300 293 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 673 677 673 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 801 808 801 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 909 916 909 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 1144 1151 1144 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 1311 1318 1311 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 1424 1431 1424 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 1565 1572 1565 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 1715 1722 1715 1722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 1833 1840 1833 1840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 1131 1138 <span type="species:ncbi:9606">persons</span>
In conclusion, we observed an excess in non-cancer mortality associated with the founder BRCA1/2 mutations among an Ashkenazi Jewish cohort, with a reduction in life expectancy of approximately 4-6 years. If real, this observed excess mortality risk in the absence of any cancer suggests that BRCA1/2 mutations may exert biologic effects quite apart from their well-established influence on cancer risk. Theoretically, these mutations may either be associated with a small increase in risk of a variety of different diseases, or they may be associated with moderate increase in risk of a few major diseases. There are currently very little available data on the effects of BRCA mutations on either overall or cause-specific mortality, and there has been no study investigating the association between BRCA1/2 mutations and non-malignant conditions. However, before speculating on specific mechanisms by which BRCA1/2 mutations might contribute to non-cancer conditions, confirmatory studies are essential. Moreover, although the findings in our study are intriguing, it is not clear whether the same findings can be generalized to persons with BRCA1/2 mutations not studied in the current cohort, or to other, non-Ashkenazi populations. Thus, additional studies, both among Ashkenazim and with other unselected BRCA1/2 carrier populations, are needed to verify this finding. Identifying underlying mechanisms for effects of BRCA1/2 on non-cancer mortality, if the finding is confirmed, could lead to a better understanding of the biological basis through which the BRCA1/2 genes exert their impact on cancer risks as well as on other non-cancer conditions. Furthermore, insights into the mechanism of action of the BRCA1/2 genes could in turn facilitate research efforts aimed at finding innovative preventive management options for BRCA1/2 mutation carriers.
###end p 52
###begin title 53
References
###end title 53
###begin article-title 54
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Risks of cancer in BRCA1-mutation carriers.
###end article-title 54
###begin article-title 55
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
###end article-title 55
###begin article-title 56
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
###end article-title 56
###begin article-title 57
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
###end article-title 57
###begin article-title 58
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
###end article-title 58
###begin article-title 59
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
###end article-title 59
###begin article-title 60
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
###end article-title 60
###begin article-title 61
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Cancer risks in BRCA2 mutation carriers.
###end article-title 61
###begin article-title 62
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
###end article-title 62
###begin article-title 63
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
###end article-title 63
###begin article-title 64
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Cancer incidence in BRCA1 mutation carriers.
###end article-title 64
###begin article-title 65
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
###end article-title 65
###begin article-title 66
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
Cellular functions of the BRCA tumour-suppressor proteins.
###end article-title 66
###begin article-title 67
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 77 82 <span type="species:ncbi:9606">women</span>
Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: An updated decision analysis.
###end article-title 67
###begin article-title 68
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 26 31 <span type="species:ncbi:9606">women</span>
Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer.
###end article-title 68
###begin article-title 69
Adjustment for competing risk in kin-cohort estimation.
###end article-title 69
###begin article-title 70
The kin-cohort study for estimating penetrance.
###end article-title 70
###begin article-title 71
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
###end article-title 71
###begin article-title 72
A marginal likelihood approach for estimating penetrance from kin-cohort designs.
###end article-title 72
###begin article-title 73
Designing studies to estimate the penetrance of an identified autosomal dominant mutation: cohort, case-control, and genotyped-proband designs.
###end article-title 73
###begin article-title 74
Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease from a kin-cohort study.
###end article-title 74
###begin article-title 75
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006.
###end article-title 75
###begin article-title 76
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
###end article-title 76
###begin article-title 77
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
###end article-title 77
###begin article-title 78
###xml 89 100 89 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/BRCA2</italic>
A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
###end article-title 78
###begin article-title 79
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
###end article-title 79
###begin article-title 80
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The National Israeli Study of Ovarian Cancer.
###end article-title 80
###begin article-title 81
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 21 26 <span type="species:ncbi:9606">women</span>
Improved survival in women with BRCA-associated ovarian carcinoma.
###end article-title 81
###begin article-title 82
###xml 67 71 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform.
###end article-title 82
###begin article-title 83
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
BRCA1 interacts with Poly(A)-binding protein: implication of BRCA1 in translation regulation.
###end article-title 83
###begin article-title 84
Absence of the full-length Breast Cancer-Associated Gene-1 leads to increased expression of Insulin-Like Growth Factor signaling axis members.
###end article-title 84
###begin p 85
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 85
###begin p 86
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This research was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 86

